It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Profiling of the antibody responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) proteins in African populations is scarce. Here, we performed a detailed IgM and IgG epitope mapping study against 487 peptides covering SARS-CoV-2 wild-type structural proteins. A panel of 41 pre-pandemic and 82 COVID-19 RT-PCR confirmed sera from Madagascar and Senegal were used. We found that the main 36 immunodominant linear epitopes identified were (i) similar in both countries, (ii) distributed mainly in the Spike and the Nucleocapsid proteins, (iii) located outside the RBD and NTD regions where most of the reported SARS-CoV-2 variant mutations occur, and (iv) identical to those reported in European, North American, and Asian studies. Within the severe group, antibody levels were inversely correlated with the viral load. This first antibody epitope mapping study performed in patients from two African countries may be helpful to guide rational peptide-based diagnostic assays or vaccine development.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Institut Pasteur de Dakar, Immunophysiopathology and Infectious Diseases Department, Dakar, Senegal (GRID:grid.418508.0) (ISNI:0000 0001 1956 9596)
2 Hesam Université, Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, EA7528, Conservatoire National des Arts et Métiers, Paris, France (GRID:grid.498415.5)
3 Institut Pasteur de Dakar, Epidemiology, Clinical Research and Data Science Department, Dakar, Senegal (GRID:grid.418508.0) (ISNI:0000 0001 1956 9596)
4 Institut Pasteur de Madagascar, Antananarivo, Madagascar (GRID:grid.418511.8) (ISNI:0000 0004 0552 7303)
5 Institut Pasteur de Dakar, Virology Department, Dakar, Senegal (GRID:grid.418508.0) (ISNI:0000 0001 1956 9596)
6 Fann University Hospital Center, Service des Maladies Infectieuses et Tropicales, Dakar, Senegal (GRID:grid.418508.0)
7 Hôpital Cochin, Bioinformatics Team, Peptinov, Paris, France (GRID:grid.411784.f) (ISNI:0000 0001 0274 3893)
8 JPT Peptide Technologies GmbH, Berlin, Germany (GRID:grid.435562.3)
9 ISoft, Bioinformatics Department, Saint-Aubin, France (GRID:grid.435562.3)